Research News

Apixaban strengthens its case in atrial fibrillation

BMJ 2012; 345 doi: https://doi.org/10.1136/bmj.e6731 (Published 10 October 2012) Cite this as: BMJ 2012;345:e6731

Apixaban is an oral anticoagulant that inhibits factor Xa. It is one of a clutch of new oral agents competing with warfarin as a first line treatment for people with atrial fibrillation. Drug trials have established that apixaban prevents more thrombotic events than warfarin and is associated with …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe